Aditxt, Inc. (ADTX)
| Market Cap | 15.67K |
| Revenue (ttm) | 14,336 -74.1% |
| Net Income | -53.34M |
| EPS | -1,380.76 |
| Shares Out | 815.92K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,093,316,294 |
| Open | 0.0200 |
| Previous Close | 0.0100 |
| Day's Range | 0.0153 - 0.0220 |
| 52-Week Range | 0.0041 - 117.8420 |
| Beta | -17.50 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 20, 2026 |
About ADTX
Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It develops ADI-100 for skin grafting, psoriasis, and type-1 diabetes. In addition, the company provides Pears... [Read more]
Financial Performance
In 2025, Aditxt's revenue was $3,195, a decrease of -97.62% compared to the previous year's $133,985. Losses were -$43.10 million, 6.81% more than in 2024.
Financial StatementsNews
Why Is Penny Stock Aditxt (ADTX) Up Today?
Aditxt stock was up on Thursday in what appears to be an instance of retail and meme traders boosting the shares higher.
Aditxt signs agreement valuing Ignite Proteomics at $150M
Aditxt (ADTX) and Ignite Proteomics, a 100%-owned subsidiary of Aditxt, announced that Ignite and strategic counterparty agreed to sign a definitive business combination agreement. The transaction val...
Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million
MOUNTAIN VIEW, Calif. & GOLDEN, Colo. & HONG KONG--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”), a qualified acquisition corp and Ignite Proteomics, LLC (“Ignite”, or “Ignite Proteomics”), ...
Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection
GOLDEN, Colo.--(BUSINESS WIRE)--Ignite Proteomics, LLC (“Ignite” or “Ignite Proteomics”) a subsidiary of Aditxt, Inc. (NASDAQ: ADTX), today announced the launch of a prospective oncology registry enro...
Aditxt appoints Busch as interim CEO
Aditxt (ADTX) announced the appointment of Jeffrey Busch as Interim Chief Executive Officer of Aditxt, effective May 31, 2026. Busch, who has served as Chief Executive Officer of Aditxt’s CLIA-certifi...
Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX)(“Aditxt” or the “Company”), a life sciences platform company accelerating promising health innovations, today announced the appointm...
Aditxt announces 1-for-27 reverse stock split
Aditxt (ADTX) announced that it will effect a 1-for-27 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on May 18, 2026,…
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced today that it will ef...
Aditxt announces publication featuring Ignite Proteomics subsidiary
Aditxt (ADTX) announced that its precision oncology subsidiary, Ignite Proteomics, has been featured in a peer-reviewed study published online ahead of print in npj Precision Oncology, a Nature journa...
Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics' RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced that its precis...
Aditxt files to sell 148.28M shares of common stock for holders
06:06 EDT Aditxt (ADTX) files to sell 148.28M shares of common stock for holders
Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the appointment...
Aditxt acquires Ignite Proteomics in $36M transaction
Aditxt (ADTX) announced the acquisition of Ignite Proteomics. Under the terms of the transaction documents, Aditxt acquired Ignite in a transaction providing 36,000 shares of Aditxt’s newly designated...
Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the acquisition...
Aditxt to effect 1-for-8 reverse split of common stock
Aditxt announced that it will effect a 1-for-8 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on March 9, the company’s…
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced today that it will ef...
3 Penny Stocks to Watch Now, 12/2/25
Pasithea Therapeutics ($KTTA), Aditxt ($ADTX), and HeartBeam ($BEAT) are the 3 Penny Stocks to watch on December 2, 2025, based on TipRanks’ Penny Stock Screener tool. Penny stocks are shares usually ...
Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today shared its growth vision ...
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced today that it will ef...
Aditxt begins enrollment in Mitomic Endometriosis Test study
Aditxt (ADTX) announced that its subsidiary, Pearsanta, has begun enrollment in their prospective clinical study evaluating the Mitomic Endometriosis Test, a novel blood-based diagnostic designed to a...
Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that its subsid...
Evofem Announces Voting Results from Special Meeting of Stockholders
-- Evofem Shareholders Did Not Approve the Merger with Aditxt -- -- Evofem Pivots to Target National Listing for Stock, Growth Capital to Catalyze Net Sales -- SAN DIEGO , Oct. 20, 2025 /PRNewswire/ -...
Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms
-- 130% increase in traffic to PHEXXI.com, the website for Evofem's hormone-free prescription contraceptive PHEXXI® (lactic acid citric acid and potassium bitartrate) -- -- PHEXXI® is #1 most followed...
Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting
-- Special Meeting to be held on September 26, 2025 -- SAN DIEGO , Sept. 9, 2025 /PRNewswire/ -- In an update to stockholders today, Evofem Biosciences, Inc. ("Evofem" or the "Company") (OTCID: EVFM) ...
Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”, or the “Company”), a social innovation platform accelerating promising health innovations, today announced an update on i...